|
|
News Breaks | | | | October 3, 2012 | | 08:40 EDT |  | ATRS | Antares Pharma 9.13M share Spot Secondary priced at $4.00
Jefferies and Oppenheimer acted as joint book running managers for the offering. | |
|
News For ATRS From The Last 14 Days Check below for free stories on ATRS the last two weeks. |
|
|
| June 13, 2013 | | 07:05 EDT |  | ATRS | Antares Pharma's auto-injection device shows positive results in clinical study
Antares Pharma announced clinical study results demonstrating that subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the treatment of adults with rheumatoid arthritis. The self-administration device is one component of an investigational product under review by the FDA that combines the company's proprietary Vibex auto-injection delivery device with an injectable version of methotrexate, the drug long regarded as the standard of care in the treatment of rheumatoid arthritis. | |
|
|
|
|
|
|
